NanoString Collaborates with MODEL-AD Consortium to Accelerate Alzheimer’s Disease Research
July 15 2019 - 6:00AM
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider
of life science tools for translational research and molecular
diagnostic products, today announced a collaboration with the
MODEL-AD consortium that has resulted in the development of two
nCounter® gene expression panels for use in Alzheimer’s disease
(AD) research, and the presentation of data from several studies at
the Alzheimer’s Association International Conference (AAIC) 2019
meeting. The development of the panels is described in detail,
highlighting that data from AD patients was used to identify the
key gene groupings to be assayed in animal models (Carter et al).
In addition, the panel was used for initial characterization of
novel mouse models of late-onset AD (Howell et al).
Historically, AD research and drug development
have been hampered by the lack of mouse models that accurately
recapitulate the disease. The MODEL-AD consortium was established
in 2016 to facilitate preclinical research in Alzheimer’s disease,
and is funded by a $25 million grant from the National Institutes
of Health (NIH). The consortium, consisting of researchers at
Indiana University (IU), The Jackson Laboratory (JAX), University
of Pittsburgh, Sage Bionetworks, and the University of California
Irvine, focuses on developing and characterizing AD animal models,
aligning them with corresponding stages of clinical disease using
translatable biomarkers, and ensuring their availability to all
researchers for use in preclinical drug development, along with
guidelines, protocols, and validation data.
“There is a need for novel mouse models of
Alzheimer’s disease as our current models are insufficient to
accurately mimic human disease,” said Bruce Lamb, Ph.D., Executive
Director of the Paul and Carole Stark Neurosciences Research
Institute at Indiana University. “A reproducible method to
characterize novel mouse models could help establish clinical gold
standards in the field.”
Working in collaboration, NanoString and
MODEL-AD consortium researchers developed two nCounter AD Panels,
one for use in mouse studies and another for use in human studies.
These panels measure the expression of 770 genes covering 30
modules discovered in a recent study of human brain tissue
(“Meta-analysis of the human brain transcriptome identifies
heterogeneity across human AD coexpression modules robust to sample
collection and methodological approach”). The collaborators have
used the Mouse AD Panel to characterize five IU/JAX MODEL-AD mouse
models to date, including the Abca7*A1527G SNP, Ceacam1 KO, hCR1
KI, Il1rap KO, and Mthfr*C677T SNP models. All data from
these studies will be made available online on the AMP-AD Knowledge
Portal (www.ampadportal.org), and the novel mouse models will be
made available from The Jackson Laboratory with no restrictions on
for-profit use.
“The AD Panels support our goal of
providing novel tools to address challenges in the field of
neurodegenerative disease research, a new and growing market for
NanoString,” said Chad Brown, NanoString’s senior vice
president of sales and marketing. “We recognize the unmet need in
AD mouse model development and disease characterization and are
glad to be supporting the MODEL-AD mission.”
“The Mouse AD panel will provide the ability to
analyze the AD-like transcriptome in the 40 new mouse models the
MODEL-AD consortium is working to develop,” said Mike Sasner,
Ph.D., research scientist at The Jackson Laboratory. “It will also
make studies in AD models more reproducible and translationally
relevant by enabling analysis of expression modules that have
previously been shown to be relevant for clinical disease.”
The nCounter Mouse AD and Human AD Panels are
currently available for purchase from NanoString. Learn more about
these products at nanostring.com/adpanels.
AAIC nCounter Mouse AD Studies
Title: A Novel Systems Biology Approach to Evaluate
Mouse Models of Late Onset Alzheimer’s Disease: nCounter Mouse AD
Panel
Lead author: Gregory Carter, Ph.D., The Jackson Laboratory,
Bar Harbor, ME, USA
Date/Time: Monday, July 15
Poster P2-105
Title: Initial Characterization of Novel Mouse Models of
Late Onset Alzheimer’s Disease Based on Human Genetic
Associations
Lead author: Gareth Howell, Ph.D., The Jackson Laboratory,
Bar Harbor, ME, USA
Date/Time: Monday, July 15
Poster P2-133
About NanoString Technologies,
Inc.
NanoString Technologies is a leading provider of
life science tools for translational research and molecular
diagnostic products. The company's nCounter® Analysis System is
used in life sciences research and has been cited in more than
2,600 peer-reviewed publications. The nCounter Analysis System
offers a cost-effective way to easily profile the expression of
hundreds of genes, proteins, miRNAs, or copy number variations,
simultaneously with high sensitivity and precision, facilitating a
wide variety of basic research and translational medicine
applications, including biomarker discovery and validation. The
company’s GeoMx™ Digital Spatial Profiler enables
highly-multiplexed spatial profiling of RNA and protein targets in
a variety of sample types, including FFPE tissue sections. The
company's technology is also being used in diagnostics. The
Prosigna® Breast Cancer Prognostic Gene Signature Assay together
with the nCounter Dx Analysis System is FDA 510(k) cleared for use
as a prognostic indicator for distant recurrence of breast
cancer.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, GeoMx,
nCounter and Prosigna are trademarks or registered trademarks of
NanoString Technologies, Inc. in various jurisdictions.
Contact:
Doug FarrellVice President, Investor Relations & Corporate
Communicationsdfarrell@nanostring.comPhone:
206-602-1768
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Apr 2023 to Apr 2024